Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from GeneDx

Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains

With major rallies and analyst backing, Nektar, Cidara, and GeneDx are drawing interest; will these biopharma firms maintain their growth trajectories?

MarketBeat

Why GeneDx, An IBD 50 Stock, Has Skyrocketed 36% Over The Past Two Days

GeneDx stock jumped again Tuesday after the American Academy of Pediatrics green-lit genetic testing for a larger pool of children.

Investors Business Daily

Jamie Dimon says AI will mean people live to 100: It's possible, says genetic testing CEO

Jamie Dimon says the next generation will live to 100, GeneDx CEO Katherine Stueland says three factors are needed to achieve this.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

Stock Market Today: Dow, S&P 500 Turn It Around As Soft Inflation Report Trumps Economic Contraction (Live Coverage)

The Dow Jones and other indexes plummeted after economic reports in the stock market today. Nvidia fell on Super Micro Computer's report.

Investors Business Daily

IBD 50's GeneDx, Down 43%, Was 'Priced For Perfection.' Here's What It Missed.

Investors hammered GeneDx stock on Wednesday after the diagnostics company beat first-quarter expectations — but not by enough.

Investors Business Daily

IBD 50's GeneDx Inks $51 Million AI-Tied Takeover Deal

IBD 50 stock GeneDx will spend up to $51 million to acquire privately held Fabric Genomics, which is working in AI-powered genomics.

Investors Business Daily

GeneDx CEO runs a $2.6 billion genetic testing business

Katherine Stueland is the CEO of GeneDx.

Fortune

Read news from The Economist, FT, and more,
with one subscription

GeneDx CEO was influenced by her family’s cystic fibrosis

Katherine Stueland is the CEO of GeneDx.

Fortune

Top Biotech GeneDx Catapults 48% After Obliterating Earnings Forecasts

GeneDx stock catapulted Tuesday after the top-notch biotech smashed fourth-quarter expectations and issued upbeat guidance.

Investors Business Daily

GeneDx: Even After Up 2,700% in 2024, Upside Is Still in Play

Saying shares of GeneDx skyrocketed in 2024 may be an understatement. As a leader in its market, upside is still a legitimate possibility for this name.

MarketBeat

IBD 50's GeneDx Adds To Nearly 2,700% Sprint With FDA Guide On AI

Shares of the IBD 50's GeneDx surged Monday after the Food and Drug Administration issued guidance about using AI to develop medical devices.

Investors Business Daily

Meta Stock, Energy Plays Lead Five Leaders Rebounding Bullishly

Meta Platforms leads five stocks flashing entries as they rebound above key moving averages within consolidations.

Investors Business Daily

How IBD Stock Of The Day GeneDx Landed On The IBD 50 And Notched A 2,500% Gain

GeneDx is Monday's IBD Stock Of The Day. Shares of the DNA-reading player are eyeing multiple buy points on a massive gain.

Investors Business Daily

This Once Ultracheap Biotech Stock Rockets 2,762%, Nears Buy Point After Big Earnings Win

Biotech stock GeneDx soared 50% after earnings on Oct. 29. Shares of the genetic testing company have soared 2,762% year to date.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

GeneDx Stock Rocketed 1,310% In Dramatic Turnaround Powered By DNA Analytics

GeneDx is helping patients navigate through the "diagnostic odyssey" with DNA sequencing. The biotech stock is on its own odyssey.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations